Advertisement
U.S. markets close in 6 hours 15 minutes

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
182.62-2.13 (-1.16%)
As of 09:41AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close184.75
Open184.17
Bid181.95 x 100
Ask185.03 x 200
Day's Range182.62 - 184.48
52 Week Range110.45 - 211.13
Volume13,395
Avg. Volume550,467
Market Cap10.185B
Beta (5Y Monthly)1.03
PE Ratio (TTM)246.78
EPS (TTM)0.74
Earnings DateApr 30, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est204.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-57% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Repligen Corporation
    RGEN: Lowering target price to $193.00REPLIGEN CORP has an Investment Rating of HOLD; a target price of $193.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Repligen Appoints Maggie A. Pax to Board of Directors

    WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she ser

  • Simply Wall St.

    Are Repligen Corporation's (NASDAQ:RGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

    It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent performance, when its stock has declined...

  • GuruFocus.com

    Repligen Corp CEO Anthony Hunt Sells 16,707 Shares

    Repligen Corp (NASDAQ:RGEN), a bioprocessing company focused on the development, manufacture, and commercialization of products used in the process of drug manufacturing, has reported an insider sale according to a recent SEC filing.